Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All quercetin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

A role for quercetin in coronavirus disease 2019 (COVID-19)

Derosa et al., Phytotherapy Research, doi:10.1002/ptr.6887
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
23rd treatment shown to reduce risk in July 2021
 
*, now with p = 0.0031 from 11 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 81 treatments. c19early.org
Review noting that quercetin has a theoretical, but significant, capability to interfere with SARS-CoV-2 replication, with results showing this to be the fifth best compound out of 18 candidates.
Reviews covering quercetin for COVID-19 include1-17.
Derosa et al., 9 Oct 2020, peer-reviewed, 4 authors.
This PaperQuercetinAll
Abstract: Received: 24 May 2020 Revised: 5 September 2020 Accepted: 13 September 2020 DOI: 10.1002/ptr.6887 REVIEW A role for quercetin in coronavirus disease 2019 (COVID-19) Giuseppe Derosa1,2 | Pamela Maffioli1 | 1 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy 2 Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy 3 Velleja Research S.r.l., Milan, Italy Correspondence Giuseppe Derosa, Department of Internal Medicine and Therapeutics, University of Pavia, Via Aselli, 43/45, 27100 Pavia, Italy. Email: giuseppe.derosa@unipv.it Angela D'Angelo2 | Francesco Di Pierro3 Several months ago, an outbreak of pneumonia of unknown aetiology was detected in Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the Chinese authorities as novel coronavirus (2019-nCoV or SARS-CoV-2). The WHO announced this new disease was to be known as “COVID-19.” When looking for new antiviral compounds, knowledge of the main viral proteins is fundamental. The major druggable targets of SARS-CoV-2 include 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase, and spike (S) protein. Quercetin inhibits 3CLpro and PLpro with a docking binding energy corresponding to −6.25 and −4.62 kcal/mol, respectively. Quercetin has a theoretical, but significant, capability to interfere with SARS-CoV-2 replication, with the results showing this to be the fifth best compound out of 18 candidates. On the basis of the clinical COVID-19 manifestations, the multifaceted aspect of quercetin as both antiinflammatory and thrombin-inhibitory actions, should be taken into consideration. KEYWORDS COVID-19, infectious diseases, nutraceutical, quercetin, SARS-CoV-2 1 | I N T RO DU CT I O N appeared in Europe. The virus was isolated in Bavaria (Germany) from a German patient infected by an individual from Shanghai (China). Viral diseases continue to pose a serious threat to public health. The Subsequently, the virus was present in Italy on January 25, 2020. The world has witnessed several viral epidemics over the past 20 years, unsuspecting individuals infected with the virus are thought to have including severe acute respiratory syndrome (SARS) coronavirus been able to circulate in the area of Basso Lodigiano with few symp- (SARS-CoV-1) in 2003, the influenza disease called H1N1 in 2009, toms or with symptoms mistaken for those of influenza. and the middle east respiratory syndrome (MERS) coronavirus (MERS- On January 30, 2020, the WHO declared the situation a public CoV) in 2012. Several months ago, an outbreak of pneumonia of health unknown aetiology was detected in Wuhan City, Province of Hubei Organization, 2020a) and on February 11, 2020, the WHO announced emergency of international concern (World Health (China) and reported to the China Country Office of the World Health that the disease caused by this new virus was to be known as Organization (WHO) on December 31, 2019. The National Health “COVID-19,” which is an acronym of “coronavirus disease-2019.” Commission of China reported the outbreak was associated with On February 20, 2020, the first symptomatic COVID-19 patient exposure in one seafood market in Wuhan City. The aetiological agent was identified in Italy at the Emergency Department of Codogno Hos- of the atypical pneumonia was isolated on January 7, 2020 by the pital, Basso Lodigiano, Province of..
{ 'indexed': {'date-parts': [[2024, 5, 1]], 'date-time': '2024-05-01T07:32:50Z', 'timestamp': 1714548770820}, 'reference-count': 46, 'publisher': 'Wiley', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2020, 10, 9]], 'date-time': '2020-10-09T00:00:00Z', 'timestamp': 1602201600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 3]]}, 'abstract': '<jats:p>Several months ago, an outbreak of pneumonia of unknown aetiology was detected in ' 'Wuhan City (China) and the aetiological agent of the atypical pneumonia was isolated by the ' 'Chinese authorities as novel coronavirus (2019‐nCoV or SARS‐CoV‐2). The WHO announced this ' 'new disease was to be known as “COVID‐19.” When looking for new antiviral compounds, ' 'knowledge of the main viral proteins is fundamental. The major druggable targets of ' 'SARS‐CoV‐2 include 3‐chymotrypsin‐like protease (3CLpro), papain‐like protease (PLpro), ' 'RNA‐dependent RNA polymerase, and spike (S) protein. Quercetin inhibits 3CLpro and PLpro with ' 'a docking binding energy corresponding to −6.25 and −4.62\u2009kcal/mol, respectively. ' 'Quercetin has a theoretical, but significant, capability to interfere with SARS‐CoV‐2 ' 'replication, with the results showing this to be the fifth best compound out of 18 ' 'candidates. On the basis of the clinical COVID‐19 manifestations, the multifaceted aspect of ' 'quercetin as both antiinflammatory and thrombin‐inhibitory actions, should be taken into ' 'consideration.</jats:p>', 'DOI': '10.1002/ptr.6887', 'type': 'journal-article', 'created': {'date-parts': [[2020, 10, 9]], 'date-time': '2020-10-09T12:10:04Z', 'timestamp': 1602245404000}, 'page': '1230-1236', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 182, 'title': 'A role for quercetin in coronavirus disease 2019 (COVID‐19)', 'prefix': '10.1002', 'volume': '35', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-3573-4760', 'authenticated-orcid': False, 'given': 'Giuseppe', 'family': 'Derosa', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Internal Medicine and Therapeutics University of ' 'Pavia Pavia Italy'}, { 'name': 'Laboratory of Molecular Medicine University of Pavia Pavia ' 'Italy'}]}, { 'given': 'Pamela', 'family': 'Maffioli', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine and Therapeutics University of ' 'Pavia Pavia Italy'}]}, { 'given': 'Angela', 'family': "D'Angelo", 'sequence': 'additional', 'affiliation': [ { 'name': 'Laboratory of Molecular Medicine University of Pavia Pavia ' 'Italy'}]}, { 'given': 'Francesco', 'family': 'Di Pierro', 'sequence': 'additional', 'affiliation': [{'name': 'Velleja Research S.r.l. Milan Italy'}]}], 'member': '311', 'published-online': {'date-parts': [[2020, 10, 9]]}, 'reference': [ { 'key': 'e_1_2_13_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1876396001104010189'}, {'key': 'e_1_2_13_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1039/C5SC02678D'}, {'key': 'e_1_2_13_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4103/0973-7847.194044'}, {'key': 'e_1_2_13_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ctim.2019.102294'}, {'key': 'e_1_2_13_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.tim.2013.05.005'}, { 'key': 'e_1_2_13_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2011.09.005'}, {'key': 'e_1_2_13_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.jcim.7b00341'}, { 'key': 'e_1_2_13_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30211-7'}, {'key': 'e_1_2_13_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/ijms20122957'}, { 'key': 'e_1_2_13_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.apjtm.2015.12.002'}, {'key': 'e_1_2_13_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/nu11102288'}, {'key': 'e_1_2_13_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.5582/ddt.2020.01012'}, {'key': 'e_1_2_13_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.00530-20'}, {'key': 'e_1_2_13_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/nprot.2016.051'}, {'key': 'e_1_2_13_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591-020-0869-5'}, { 'key': 'e_1_2_13_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phrs.2010.05.001'}, { 'key': 'e_1_2_13_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30183-5'}, { 'key': 'e_1_2_13_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.01.009'}, {'key': 'e_1_2_13_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cbdd.13604'}, { 'key': 'e_1_2_13_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/14756366.2019.1690480'}, { 'key': 'e_1_2_13_22_1', 'first-page': '2020030226', 'article-title': 'Potential inhibitor of COVID‐19 main protease (Mpro) from several ' 'medicinal plant compounds by molecular docking study', 'author': 'Khaerunnisa S.', 'year': '2020', 'journal-title': 'Preprints'}, { 'key': 'e_1_2_13_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.autrev.2019.05.001'}, { 'key': 'e_1_2_13_24_1', 'first-page': '22', 'article-title': 'Quercetin: A versatile flavonoid', 'volume': '2', 'author': 'Lakhanpal P.', 'year': '2007', 'journal-title': 'International Journal of Medicine'}, {'key': 'e_1_2_13_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M20-0504'}, {'key': 'e_1_2_13_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001316'}, {'key': 'e_1_2_13_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcc.20186'}, { 'key': 'e_1_2_13_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.thromres.2010.08.006'}, {'key': 'e_1_2_13_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.25761'}, { 'key': 'e_1_2_13_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13020-020-00317-x'}, { 'key': 'e_1_2_13_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.virusres.2020.197989'}, {'key': 'e_1_2_13_32_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2298/VSP1511951M'}, {'key': 'e_1_2_13_33_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s10529-011-0845-8'}, {'key': 'e_1_2_13_34_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12272-012-0108-9'}, { 'key': 'e_1_2_13_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/14756366.2016.1265519'}, { 'key': 'e_1_2_13_36_1', 'article-title': 'Repurposing therapeutics for COVID‐19: Supercomputer‐based docking to ' 'the SARS‐CoV‐2 viral spike protein and viral spike protein‐human ACE2 ' 'interface', 'author': 'Smith M.', 'year': '2020', 'journal-title': 'ChemRxiv'}, {'key': 'e_1_2_13_37_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1743-422X-8-460'}, { 'key': 'e_1_2_13_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phymed.2015.10.018'}, {'key': 'e_1_2_13_39_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/jm034137m'}, {'key': 'e_1_2_13_40_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2004973'}, {'key': 'e_1_2_13_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00726-006-0403-1'}, {'key': 'e_1_2_13_42_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.1585'}, { 'key': 'e_1_2_13_43_1', 'unstructured': 'World Health Organization. ' '(2020a).https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)'}, { 'key': 'e_1_2_13_44_1', 'unstructured': 'World Health Organization. ' '(2020b).https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---26-february-2020'}, { 'key': 'e_1_2_13_45_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.joim.2020.02.005'}, { 'key': 'e_1_2_13_46_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.clim.2020.108393'}, {'key': 'e_1_2_13_47_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiaa228'}], 'container-title': 'Phytotherapy Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.6887', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ptr.6887', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.6887', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 2]], 'date-time': '2023-09-02T03:14:35Z', 'timestamp': 1693624475000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/ptr.6887'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10, 9]]}, 'references-count': 46, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2021, 3]]}}, 'alternative-id': ['10.1002/ptr.6887'], 'URL': 'http://dx.doi.org/10.1002/ptr.6887', 'relation': {}, 'ISSN': ['0951-418X', '1099-1573'], 'subject': [], 'container-title-short': 'Phytotherapy Research', 'published': {'date-parts': [[2020, 10, 9]]}, 'assertion': [ { 'value': '2020-05-24', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-09-13', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-10-09', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit